<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02395354</url>
  </required_header>
  <id_info>
    <org_study_id>ProtDilat-3-2013</org_study_id>
    <nct_id>NCT02395354</nct_id>
  </id_info>
  <brief_title>Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease</brief_title>
  <acronym>PROTDILAT</acronym>
  <official_title>Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease: Metal Self-expanding Prosthesis Balloon Dilatation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a multicentre randomized controlled trial to assess the efficacy between
      balloon dilatation and self-expanding metallic stent placement for endoscopic treatment of
      stenosis in Crohn´s Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Prospective, randomized, multicenter clinical trial.

      Duration: Beginning in mid-2013 with a minimum of three years depending on the patient
      inclusion rate.

      The participation of at least 20 hospitals in Spain with an inclusion of about 6 patients per
      hospital is required.

      Calculation of sample size: The calculation of sample size was performed considering that the
      efficacy of endoscopic treatment by endoscopic stent placement is superior to endoscopic
      dilatation: 75% vs 50% for balloon dilation (% of patients free of therapeutic intervention
      -endoscopic or surgically a year follow-up).

      For all 61 patients are required for each treatment group, the total of 122 patients. This
      calculation is made taking into account:

        -  Bilateral Contrast: any two samples may be superior in terms of efficacy.

        -  Error type I: 0.05

        -  Error type II: 0.20 (statistical power 80%)

        -  Percentage of efficacy at one year follow-up: 75% in the prosthetic group and 50% in the
           balloon dilatation group

        -  Percentage of losses: 5%.

      Schedule

        1. Screening Visit

        2. Sheet Inclusion

        3. Expansion notebook / prosthesis placement notebook

        4. Monitoring Worksheet to the 7 days. Symptomatic / complications-incidents assessment.

        5. Monitoring Worksheet to the 30 days. Symptomatic / complications-incidents assessment.
           Includes analytical. In case of placement of prostheses include prosthetic removal sheet

        6. Monitoring Worksheet to the 2 months. Symptomatic / complications-incidents assessment.

        7. Monitoring Worksheet to the 3 months. Symptomatic / complications-incidents assessment.

        8. Monitoring Worksheet to the 4 months. Symptomatic / complications-incidents assessment

        9. Monitoring Worksheet to the 5 months. Symptomatic / complications-incidents assessment

       10. Monitoring Worksheet to the 6 months. Symptomatic / complications-incidents assessment.
           Include analytical

       11. Monitoring Worksheet to the 7 months. Symptomatic / complications-incidents assessment

       12. Monitoring Worksheet to the 8 months. Symptomatic / complications-incidents assessment

       13. Monitoring Worksheet to the 9 months. Symptomatic / complications-incidents assessment

       14. Monitoring Worksheet to the 10 months. Symptomatic / complications-incidents assessment

       15. Monitoring Worksheet to the 11 months. Symptomatic / complications-incidents assessment

       16. Monitoring Worksheet to the 12 months. Symptomatic / complications-incidents assessment
           Include analytical.

       17. Final assessment.

       18. Monitoring Worksheet to the recurrence. Symptomatic / complications-incidents
           assessment. Include analytical
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2013</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage (%) of free patients of therapeutic intervention (dilatation, prosthesis or surgery) for symptomatic recurrence at one year follow-up</measure>
    <time_frame>one year follow-up</time_frame>
    <description>To evaluate the efficacy of endoscopic treatment (prosthesis vs dilation), determined by the percentage of free patients of a new therapeutic intervention (dilatation, prosthesis or surgery) for symptomatic recurrence at one year follow-up.
Symptomatic recurrence assessment:
It will be performed through an obstructive symptoms scale previously described (Attar et al, Safety and efficacy of extractible self-expandable metal stents in the treatment of Crohn's disease intestinal strictures: A prospective pilot study. Inflamm Bowel Dis. 2011 Dec 11).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of free patients of therapeutic intervention (dilatation, prosthesis or surgery) for symptomatic recurrence at 6 months follow-up.</measure>
    <time_frame>At 6 months follow-up</time_frame>
    <description>To evaluate the efficacy of endoscopic treatment (prosthesis vs dilation), determined by the percentage of patients free of therapeutic intervention (dilatation, prosthesis or surgery) for symptomatic recurrence at 6 months follow-up.
Symptomatic recurrence assessment:
It will be performed through an obstructive symptoms scale previously described (Attar et al, Safety and efficacy of extractible self-expandable metal stents in the treatment of Crohn's disease intestinal strictures: A prospective pilot study. Inflamm Bowel Dis. 2011 Dec 11).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complications related to the procedure.</measure>
    <time_frame>one year follow-up</time_frame>
    <description>Evaluate the safety and complications of both treatments
Immediate complications related to the procedure:
Inhaled into the lungs.
Respiratory depression O2 Sat &lt;90%
Cardiorespiratory arrest
Arrhythmia
Allergic reaction
Pain
Hemorrhage: self-limiting (spontaneous hemostasis) / accurate endoscopic treatment (drooling bleeding / bleeding jet).
Piercing: endoscopic treatment / surgery treatment
Exitus
Others
Late complications related to the procedure:
Pain
Hemorrhage: self-limiting (spontaneous hemostasis) / accurate endoscopic treatment (drooling bleeding / bleeding jet).
Piercing: endoscopic treatment / surgery treatment
Exitus
Others</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The procedure total costs</measure>
    <time_frame>one year follow-up</time_frame>
    <description>Evaluate the costs of both treatments
Study costs:
The calculate procedure of diagnostic test (DT) cost is composed of some premises:
Calculate the test unit cost
Accounting for all costs associated with DT Direct and Indirect Costs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Stenosis</condition>
  <condition>Crohn's Disease</condition>
  <condition>Chronic Inflammation</condition>
  <arm_group>
    <arm_group_label>Placing a self-expanding metallic stent</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placing a self-expanding metallic stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A balloon dilatation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A balloon dilatation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placing a self-expanding metallic stent</intervention_name>
    <description>Income on short stay unit (SSU) post-procedure
Light sedation by the endoscopist vs anesthetist by center
Fully covered self-expanding metal stents Tae Woong Medical® type; prosthesis size at the endoscopist discretion
Clips can be placed at the distal end of the prosthesis according to the endoscopist.
Prosthesis removal time in 4 weeks.</description>
    <arm_group_label>Placing a self-expanding metallic stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>A balloon dilatation</intervention_name>
    <description>Income on short stay unit (SSU) post-procedure
Light sedation by the endoscopist vs anesthetist by center.
Pneumatic ball type CRE Boston cientific®; balloon diameter at the endoscopist discretion
Up to 2 expansion will be made with a minimum interval between 15-30 days between each expansion
It shall be deemed failure to expansion if required&gt; 2 expansions.</description>
    <arm_group_label>A balloon dilatation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-75 years.

          -  Crohn's Disease with a predominantly fibrotic stenosis de novo and / or post- surgical
             confirmed by endoscopic and radiological tests, accessible by endoscopy (colonoscopy).

          -  Patients with stenosis already known and previously treated with stent and / or
             dilation with&gt; 1 Year asymptomatic

          -  Symptoms of intestinal partial occlusion

          -  Refractory to Conventional medical treatment (no response to usual therapeutic range
             &quot;accelerated step-up&quot;).

          -  Length of stenosis &lt;10 cm.

          -  Submit a maximum of 2 stenosis.

          -  Patient Informed consent

        Exclusion Criteria:

          -  No patient Informed consent.

          -  Stenosis complicated with abscess, fistula or important activity associated with your
             EC not limited to the stenosis area.

          -  Patients with stenosis already known and previously treated with stent and / or
             dilation with &lt;1 year asymptomatic.

          -  Pregnancy and lactation

          -  Any clinical situation that prevents the performance of endoscopy

          -  Stenosis not accessible by endoscopy

          -  Asymptomatic patient

          -  Length of stenosis ≥ 10 cm.

          -  Submit&gt; 2 stenosis.

          -  Severe coagulation disorders (platelets &lt;70000; INR&gt; 1.8)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carme Loras, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari Mutua de Terrassa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carme Loras, MD</last_name>
    <phone>+34-937365050</phone>
    <phone_ext>1215</phone_ext>
    <email>cloras@mutuaterrassa.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>María Esteve, MD</last_name>
    <phone>+34-937365050</phone>
    <email>mestevecomas@telefonica.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Unversitari Mutua de Terrasa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carme Loras, MD</last_name>
      <phone>+34937365050</phone>
      <phone_ext>1215</phone_ext>
      <email>cloras@mutuaterrassa.es</email>
    </contact>
    <contact_backup>
      <last_name>Maria Esteve, MD</last_name>
      <phone>+34937365050</phone>
      <email>mestevecomas@telefonica.net</email>
    </contact_backup>
    <investigator>
      <last_name>Carme Loras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, Gendre JP. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002 Jul;8(4):244-50.</citation>
    <PMID>12131607</PMID>
  </reference>
  <reference>
    <citation>Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990 Oct;99(4):956-63.</citation>
    <PMID>2394349</PMID>
  </reference>
  <reference>
    <citation>Hommes DW, van Deventer SJ. Endoscopy in inflammatory bowel diseases. Gastroenterology. 2004 May;126(6):1561-73. Review.</citation>
    <PMID>15168367</PMID>
  </reference>
  <reference>
    <citation>Tichansky D, Cagir B, Yoo E, Marcus SM, Fry RD. Strictureplasty for Crohn's disease: meta-analysis. Dis Colon Rectum. 2000 Jul;43(7):911-9.</citation>
    <PMID>10910235</PMID>
  </reference>
  <reference>
    <citation>Hassan C, Zullo A, De Francesco V, Ierardi E, Giustini M, Pitidis A, Taggi F, Winn S, Morini S. Systematic review: Endoscopic dilatation in Crohn's disease. Aliment Pharmacol Ther. 2007 Dec;26(11-12):1457-64. Epub 2007 Sep 28. Review.</citation>
    <PMID>17903236</PMID>
  </reference>
  <reference>
    <citation>Thienpont C, D'Hoore A, Vermeire S, Demedts I, Bisschops R, Coremans G, Rutgeerts P, Van Assche G. Long-term outcome of endoscopic dilatation in patients with Crohn's disease is not affected by disease activity or medical therapy. Gut. 2010 Mar;59(3):320-4. doi: 10.1136/gut.2009.180182. Epub 2009 Oct 19. Erratum in: Gut. 2010 Jul;59(7):1007.</citation>
    <PMID>19840991</PMID>
  </reference>
  <reference>
    <citation>Matsuhashi N, Nakajima A, Suzuki A, Yazaki Y, Takazoe M. Long-term outcome of non-surgical strictureplasty using metallic stents for intestinal strictures in Crohn's disease. Gastrointest Endosc. 2000 Mar;51(3):343-5.</citation>
    <PMID>10699786</PMID>
  </reference>
  <reference>
    <citation>Wholey MH, Levine EA, Ferral H, Castaneda-Zuniga W. Initial clinical experience with colonic stent placement. Am J Surg. 1998 Mar;175(3):194-7.</citation>
    <PMID>9560118</PMID>
  </reference>
  <reference>
    <citation>Suzuki N, Saunders BP, Thomas-Gibson S, Akle C, Marshall M, Halligan S. Colorectal stenting for malignant and benign disease: outcomes in colorectal stenting. Dis Colon Rectum. 2004 Jul;47(7):1201-7. Epub 2004 Jun 3.</citation>
    <PMID>15164246</PMID>
  </reference>
  <reference>
    <citation>Wada H, Mochizuki Y, Takazoe M, Matsuhashi N, Kitou F, Fukushima T. A case of perforation and fistula formation resulting from metallic stent for sigmoid colon stricture in Crohn's disease. Tech Coloproctol. 2005 Apr;9(1):53-6.</citation>
    <PMID>15868501</PMID>
  </reference>
  <reference>
    <citation>Bickston SJ, Foley E, Lawrence C, Rockoff T, Shaffer HA Jr, Yeaton P. Terminal ileal stricture in Crohn's disease: treatment using a metallic enteral endoprosthesis. Dis Colon Rectum. 2005 May;48(5):1081-5.</citation>
    <PMID>15785899</PMID>
  </reference>
  <reference>
    <citation>Dafnis G. Repeated coaxial colonic stenting in the palliative management of benign colonic obstruction. Eur J Gastroenterol Hepatol. 2007 Jan;19(1):83-6.</citation>
    <PMID>17206082</PMID>
  </reference>
  <reference>
    <citation>Martines G, Ugenti I, Giovanni M, Memeo R, Iambrenghi OC. Anastomotic stricture in Crohn's disease: bridge to surgery using a metallic endoprosthesis. Inflamm Bowel Dis. 2008 Feb;14(2):291-2.</citation>
    <PMID>17924567</PMID>
  </reference>
  <reference>
    <citation>Small AJ, Young-Fadok TM, Baron TH. Expandable metal stent placement for benign colorectal obstruction: outcomes for 23 cases. Surg Endosc. 2008 Feb;22(2):454-62.</citation>
    <PMID>17704890</PMID>
  </reference>
  <reference>
    <citation>Keränen I, Lepistö A, Udd M, Halttunen J, Kylänpää L. Outcome of patients after endoluminal stent placement for benign colorectal obstruction. Scand J Gastroenterol. 2010 Jun;45(6):725-31. doi: 10.3109/00365521003663696.</citation>
    <PMID>20205505</PMID>
  </reference>
  <reference>
    <citation>Attar A, Maunoury V, Vahedi K, Vernier-Massouille G, Vida S, Bulois P, Colombel JF, Bouhnik Y; GETAID. Safety and efficacy of extractible self-expandable metal stents in the treatment of Crohn's disease intestinal strictures: a prospective pilot study. Inflamm Bowel Dis. 2012 Oct;18(10):1849-54. doi: 10.1002/ibd.22844. Epub 2011 Dec 11.</citation>
    <PMID>22161935</PMID>
  </reference>
  <reference>
    <citation>Levine RA, Wasvary H, Kadro O. Endoprosthetic management of refractory ileocolonic anastomotic strictures after resection for Crohn's disease: report of nine-year follow-up and review of the literature. Inflamm Bowel Dis. 2012 Mar;18(3):506-12. doi: 10.1002/ibd.21739. Epub 2011 May 3. Review.</citation>
    <PMID>21542067</PMID>
  </reference>
  <reference>
    <citation>Loras C, Pérez-Roldan F, Gornals JB, Barrio J, Igea F, González-Huix F, González-Carro P, Pérez-Miranda M, Espinós JC, Fernández-Bañares F, Esteve M. Endoscopic treatment with self-expanding metal stents for Crohn’s disease strictures. Aliment Pharmacol Ther. 2012 Nov;36(9):833-9.</citation>
    <PMID>22966851</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2015</study_first_submitted>
  <study_first_submitted_qc>March 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2015</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endoscopic treatment</keyword>
  <keyword>Stenosis</keyword>
  <keyword>Crohn's Disease</keyword>
  <keyword>balloon dilatation</keyword>
  <keyword>self-expanding metallic stent</keyword>
  <keyword>chronic transmural inflammation</keyword>
  <keyword>steady narrowing of the intestinal lumen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

